双靶点基因治疗帕金森病:多中心1期试验
这项多中心、开放标签、剂量递增1期试验评估了AAVT42载体共递送持续活性TH和AADC的BBM-P002治疗帕金森病的安全性与耐受性。10例中重度患者接受双侧壳核内输注,12个月内未出现剂量限制性毒性或药物相关严重不良事件,23例不良事件均判定与药物无关,支持继续临床开发。
要点
- BBM-P002双侧壳核内输注在12个月内安全且耐受良好。
- 未发生剂量限制性毒性或药物相关严重不良事件。
- 共报告23例不良事件,均判定与BBM-P002无关且多为轻度和一过性。
核心结论
- BBM-P002壳核内输注在1期试验中安全且耐受良好,支持继续临床开发。
研究设计与样本
- 多中心、开放标签、剂量递增1期试验,评估AAVT42载体共递送持续活性TH和AADC的BBM-P002。
- 纳入10例中重度帕金森病患者,接受双侧壳核内输注。
- 剂量分别为4.0 × 10^11 vg(队列1,n=1)、6.0 × 10^11 vg(队列2,n=2)、1.0 × 10^12 vg(队列3,n=2)和1.2 × 10^12 vg(队列4,n=5)。
主要发现
- 试验达到主要终点,BBM-P002在治疗后12个月内表现出良好的安全性和耐受性。
- 未发生剂量限制性毒性或药物相关严重不良事件。
- 共报告23例不良事件,均判定与BBM-P002无关,主要为轻度和一过性。
- 未观察到全身毒性和有临床意义的免疫原性。
临床怎么用
- 该1期结果支持BBM-P002后续临床开发,尚不能用于临床常规治疗决策。
局限性
- 开放标签设计,样本量小(10例),各剂量队列人数不等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Restoring striatal dopamine synthesis is a promising gene therapy strategy for Parkinson's disease. Previous adeno-associated virus-mediated aromatic L-amino acid decarboxylase (AADC) monotherapies remain dependent on exogenous levodopa, whereas multigene delivery is constrained by strict adeno-associated virus packaging limits. A 'dual approach' targeting the two rate-limiting enzymes, tyrosine hydroxylase (TH) and AADC, offers the potential for autonomous dopamine synthesis. We report the 12-month primary safety and tolerability outcomes of a multicenter, open-label, dose-escalation, phase 1 trial evaluating BBM-P002, a new adeno-associated virus vector-AAVT42-codelivering constitutively active TH and AADC. Ten participants with moderate-to-advanced Parkinson's disease were enrolled and received bilateral intraputaminal infusions across doses of 4.0 × 1011 vg (Cohort 1; n = 1), 6.0 × 1011 vg (Cohort 2; n = 2), 1.0 × 1012 vg (Cohort 3; n = 2) and 1.2 × 1012 vg (Cohort 4; n = 5). The trial achieved its primary outcome, as BBM-P002 demonstrated a favorable safety and tolerability profile within 12 months post-treatment. No dose-limiting toxicities or drug-related serious adverse events occurred. A total of 23 adverse events were reported, all judged unrelated to BBM-P002 and primarily mild and transient. Systemic toxicity and clinically meaningful immunogenicity were absent. In conclusion, intraputaminal delivery of BBM-P002 was safe and well tolerated in this phase 1 trial, supporting continued clinical development. ClinicalTrials.gov registration: NCT05822739 .
引用
- Niu M, Guo J, Yang Y, et al. Dual-target gene therapy in Parkinson's disease: a multicenter phase 1 trial. Nat Med. 2026. PMID: 42271071. doi:10.1038/s41591-026-04436-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。